Biogen stops clinical trial tracking Aduhelm


Biogen Inc. BIIB, +0.26% said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer’s disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company updated the study’s listing with this information on Tuesday. The prospective, multi-center study planned to track patients taking Aduhelm for five years. The Food and Drug Administration approved Aduhelm a year ago, but the Centers for Medicare and Medicaid Services later said it will cover Adhulm only if patients are enrolled in a clinical trial. Biogen still plans to move forward with a Phase 4 clinical trial for Aduhelm called Envision. The company’s stock is down 11.9% this year, while the broader S&P 500 SPX, +3.06% has declined 20.3%.

This article was originally published by Read the original article here.

Previous article: Inflation is forcing Americans to change their diets: ‘We make vegetable soup’
Next article: Supreme Court overturns Roe v. Wade: 40 million women will now lose access to abortion


Please enter your comment!
Please enter your name here